WPD Pharmaceuticals Inc
WPD Pharmaceuticals Inc. does not have any significant operations. Previously, it was engaged in the research and development of medicinal products in the fields of oncology. The company is headquartered in Vancouver, Canada.
WPD Pharmaceuticals Inc (WPDPF) - Net Assets
Latest net assets as of September 2024: $-622.29K USD
Based on the latest financial reports, WPD Pharmaceuticals Inc (WPDPF) has net assets worth $-622.29K USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($292.54K) and total liabilities ($914.82K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-622.29K |
| % of Total Assets | -212.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | -117.33% |
| 10-Year Change | N/A |
| Growth Volatility | 181.89 |
WPD Pharmaceuticals Inc - Net Assets Trend (2006–2023)
This chart illustrates how WPD Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for WPD Pharmaceuticals Inc (2006–2023)
The table below shows the annual net assets of WPD Pharmaceuticals Inc from 2006 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-555.96K | -16.12% |
| 2022-12-31 | $-478.79K | +88.20% |
| 2021-12-31 | $-4.06 Million | -466.42% |
| 2020-12-31 | $1.11 Million | -65.48% |
| 2019-12-31 | $3.21 Million | +229.41% |
| 2018-12-31 | $973.92K | +212.95% |
| 2017-12-31 | $311.20K | +222.80% |
| 2016-12-31 | $-253.41K | -353.60% |
| 2015-12-31 | $-55.87K | -65.31% |
| 2014-12-31 | $-33.80K | -1863.68% |
| 2013-12-31 | $-1.72K | -101.50% |
| 2012-12-31 | $115.00K | -47.71% |
| 2011-12-31 | $219.93K | -51.92% |
| 2010-12-31 | $457.45K | -26.22% |
| 2009-12-31 | $620.04K | -9.13% |
| 2008-12-31 | $682.33K | +50.58% |
| 2007-12-31 | $453.12K | +37860.25% |
| 2006-12-31 | $-1.20K | -- |
Equity Component Analysis
This analysis shows how different components contribute to WPD Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2201186900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.08 Million | % |
| Other Comprehensive Income | $4.37 Million | % |
| Other Components | $2.92K | % |
| Total Equity | $-555.96K | 100.00% |
WPD Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of WPD Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
$77.95K |
|
GCI Liberty, Inc. Series C Purchase Right
NASDAQ:GLIBR
|
$78.03K |
|
Graycliff Exploration Limited
PINK:GRYCF
|
$78.04K |
|
VALUE-HOLDINGS
MU:VHO
|
$78.05K |
|
Ather Energy Limited
NSE:ATHERENERG
|
$77.93K |
|
Barr (A G) PLC
STU:AF72
|
$77.87K |
|
KEPPEL (KEP1.SG)
STU:KEP1
|
$77.78K |
|
HARMONIC (HMC.SG)
STU:HMC
|
$77.67K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in WPD Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -478,792 to -555,958, a change of -77,166.
- Net loss of 80,082 reduced equity.
- Other factors increased equity by 2,916.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-80.08K | -14.4% |
| Other Changes | $2.92K | +0.52% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares WPD Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.00 | $0.00 | x |
| 2007-12-31 | $0.54 | $0.00 | x |
| 2008-12-31 | $0.34 | $0.00 | x |
| 2009-12-31 | $0.27 | $0.00 | x |
| 2010-12-31 | $0.17 | $0.00 | x |
| 2011-12-31 | $0.08 | $0.00 | x |
| 2012-12-31 | $0.04 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $-0.01 | $0.00 | x |
| 2015-12-31 | $-0.02 | $0.00 | x |
| 2016-12-31 | $-0.09 | $0.00 | x |
| 2017-12-31 | $0.05 | $0.00 | x |
| 2018-12-31 | $0.05 | $0.00 | x |
| 2019-12-31 | $0.04 | $0.00 | x |
| 2020-12-31 | $0.01 | $0.00 | x |
| 2021-12-31 | $-0.04 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently WPD Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-88.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.08K |
| 2007 | -0.15% | 0.00% | 0.00x | 1.02x | $-45.99K |
| 2008 | -24.78% | 0.00% | 0.00x | 1.01x | $-237.34K |
| 2009 | -56.75% | 0.00% | 0.00x | 1.06x | $-413.86K |
| 2010 | -41.12% | 0.00% | 0.00x | 1.03x | $-233.83K |
| 2011 | -83.18% | 0.00% | 0.00x | 1.06x | $-204.92K |
| 2012 | -100.12% | 0.00% | 0.00x | 1.12x | $-126.64K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-116.55K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-56.35K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.49K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-178.79K |
| 2017 | -136.05% | 0.00% | 0.00x | 1.31x | $-454.50K |
| 2018 | -80.03% | 0.00% | 0.00x | 4.04x | $-876.83K |
| 2019 | -398.25% | 0.00% | 0.00x | 1.27x | $-13.10 Million |
| 2020 | -679.20% | 0.00% | 0.00x | 2.42x | $-7.63 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.22 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $3.91 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.49K |
Industry Comparison
This section compares WPD Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| WPD Pharmaceuticals Inc (WPDPF) | $-622.29K | 0.00% | N/A | $77.94K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |